NCT04015570

Brief Summary

In this randomized study subject will be randomized into two groups Group A will receive Standard Medical Treatment (Albumin + High Caloric Diet) Group B will continue Standard Medical Treatment with High Volume Plasma Exchange. All other interventions will be at the discretion of clinicians.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jul 2019

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 8, 2019

Completed
1 day until next milestone

Study Start

First participant enrolled

July 9, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 11, 2019

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2020

Completed
Last Updated

July 11, 2019

Status Verified

July 1, 2019

Enrollment Period

12 months

First QC Date

July 8, 2019

Last Update Submit

July 9, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Transplant free survival in both group

    Day 28

Secondary Outcomes (3)

  • Number of participants with the development of organ dysfunction or failure in both group

    Day 7

  • Number of participants with the development of organ dysfunction or failure in both group

    Day 15

  • Number of participants with the development of organ dysfunction or failure in both group

    Day 28

Study Arms (2)

High Volume Plasma Exchange with SMT

EXPERIMENTAL

PLASMA EXCHANGE is therapeutic procedure in which blood of the patient is passed through a medical device which separates plasma from other components of blood. The plasma is removed and replaced with a replacement solution such as colloid solution (e.g., albumin and/or plasma) or a combination of crystalloid/colloid solution.Plasma exchange leads to removal of abnormal circulating plasma factor or a physiologic factor produced in excess (IG, NH3,protein bond toxins )and also exert a immunomodulatory activity. Standard Medical Treatment (Albumin + High Caloric Diet)

Biological: High Volume Plasma ExchangeOther: Standard Medical Treatment

Standard Medical Treatment

ACTIVE COMPARATOR

Standard Medical Treatment (Albumin + High Caloric Diet)

Other: Standard Medical Treatment

Interventions

PLASMA EXCHANGE is therapeutic procedure in which blood of the patient is passed through a medical device which separates plasma from other components of blood. The plasma is removed and replaced with a replacement solution such as colloid solution (e.g., albumin and/or plasma) or a combination of crystalloid/colloid solution.Plasma exchange leads to removal of abnormal circulating plasma factor or a physiologic factor produced in excess (IG, NH3,protein bond toxins )and also exert a immunomodulatory activity

High Volume Plasma Exchange with SMT

Standard Medical Treatment (Albumin+High caloric diet)

High Volume Plasma Exchange with SMTStandard Medical Treatment

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age-18-70 years
  • Preferably Biopsy proven or history suggestive of DILI (Drug Induced Liver Injury)
  • Grade IV DILI With T.B \> 15
  • DILI Manifesting as ACLF (Acute on chronic Liver failure) /ALF (Acute Liver Failure) with no transplant option

You may not qualify if:

  • Evidence of active infection
  • Refusal of consent or assent
  • Patients with clinical suspicion of irreversible brain injury
  • Pregnancy
  • HCC (Hepatocellular Carcinoma) or any other malignancy
  • Kidney failure
  • Portal vein thrombosis
  • Upper GastroIntestinal bleed
  • Transplant

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Institute of Liver & Biliary Sciences

New Delhi, National Capital Territory of Delhi, 110070, India

RECRUITING

Central Study Contacts

Dr Satyam Sinha, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 8, 2019

First Posted

July 11, 2019

Study Start

July 9, 2019

Primary Completion

July 1, 2020

Study Completion

July 1, 2020

Last Updated

July 11, 2019

Record last verified: 2019-07

Locations